Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Pheochromocytoma 1Paraganglioma 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Oxyphilic 1Adenocarcinoma, Follicular 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1motesanib diphosphate 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1cediranib 1Sorafenib 1Sodium Iodide 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × spartalizumab × Endocrine × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡